Stocks Health care AGIO
NASDAQ · Health careAgios Pharmaceuticals, Inc. (AGIO)
Agios Pharmaceuticals, Inc. brought in $140.8M of revenue over the twelve months to September 30, 2026, up 214.4% from a year earlier. It posted a net loss of $372.9M. In fiscal 2025 capital spending exceeded operating cash flow by $377.3M. At September 30, 2026 it held $128.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Agios Pharmaceuticals, Inc.
- Net worth
- Agios Pharmaceuticals, Inc. has a market value (market cap) of $1.9B at the latest share price, and shareholders' equity of $979.3M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $54M (+48.0% year on year), with a net loss of $412.8M. Over the 12 months to September 30, 2026: revenue $140.8M, net loss $372.9M.
- Cash flow
- In fiscal 2025 operations used $373M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Agios Pharmaceuticals, Inc.'s next report is expected around February 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Agios Pharmaceuticals, Inc. does
Agios Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker AGIO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $54M | -$412.8M | -$7.12 | -$377.3M |
| 2024 | $36.5M | $673.7M | $11.64 | -$391.5M |
| 2023 | $26.8M | -$352.1M | -$6.33 | -$297.1M |
| 2022 | $14.2M | -$231.8M | -$4.23 | -$314.4M |
| 2021 | $0 | $1.6B | $26.55 | -$413.1M |
| 2020 | $0 | -$327.4M | -$4.74 | -$304.9M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where AGIO ranks in Health care
Latest SEC filings
What Agios Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 330% to $55.4M versus the same quarter last year; diluted EPS -$1.09 versus -$1.78.
- November 5, 2026
- August 3, 2026Passive stake changed SCHEDULE 13G/A
- July 30, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 259% to $44.7M versus the same quarter last year; diluted EPS -$1.69 versus -$1.93.
- July 30, 2026
- July 2, 2026Passive stake (5% or more) SCHEDULE 13G
- June 18, 2026
- June 18, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 6, 2026Passive stake (5% or more) SCHEDULE 13G
Insider trades
What the people running Agios Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $371.1K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 26, 2026 | Gheuens SarahChief Medical Officer | Exercised options | 7,866 | $196.7K |
| October 26, 2026 | Gheuens SarahChief Medical Officer | Soldpre-planned (10b5-1) | 7,866 | $296.5K |
| October 22, 2026 | Gheuens SarahChief Medical Officer | Exercised options | 500 | $12.5K |
| October 22, 2026 | Gheuens SarahChief Medical Officer | Soldpre-planned (10b5-1) | 500 | $18.8K |
| October 21, 2026 | Gheuens SarahChief Medical Officer | Exercised options | 1,489 | $37.2K |
| October 21, 2026 | Gheuens SarahChief Medical Officer | Soldpre-planned (10b5-1) | 1,489 | $55.9K |
| August 4, 2026 | Gheuens SarahChief Medical Officer | Soldpre-planned (10b5-1) | 30,000 | $914.4K |
| July 8, 2026 | Backstrom Jay T.Director | Received as pay | 1,447 | - |
Who owns AGIO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Farallon Capital Management, L.L.C.13G, passive with 28 related filers | 9.9% | August 3, 2026 |
| Dapice Joshua J.13G, passive with 30 related filers | 8.8% | February 9, 2026 |
| Vanguard Capital Management13G, passive | 5.27% | April 29, 2026 |
| D. E. Shaw & Co., L.P.13G, passive with 1 related filers | 5.1% | July 2, 2026 |
| Lynx1 Capital Management LP13G, passive with 1 related filers | 5.1% | May 6, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 238 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 6,455,997 | +701,040 |
| Farallon Capital Management, L.L.C. | 5,917,400 | +233,400 |
| State Street Corp | 3,533,633 | +168,754 |
| Lynx1 Capital Management LP | 3,408,937 | +797,369 |
| D. E. Shaw & Co., Inc. | 3,107,005 | +425,836 |
| Vanguard Portfolio Management LLC | 2,898,197 | +287,162 |
| Vanguard Capital Management LLC | 2,681,845 | +49,529 |
| Armistice Capital, LLC | 2,400,000 | -316,000 |
| Erste Asset Management GmbH | 2,154,900 | -550,000 |
| Nomura Asset Management International Inc. | 2,110,809 | +616,374 |
| Geode Capital Management, LLC | 1,574,268 | +106,358 |
| Susquehanna International Group, Llp | 1,375,558 | +30,605 |
| ADAR1 Capital Management, LLC | 1,288,053 | +1,147,381 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1,280,044 | -300,796 |
| Dimensional Fund Advisors LP | 1,248,738 | +97,124 |
| Goldman Sachs Group Inc | 1,150,932 | +345,156 |
| UBS Group AG | 985,831 | +853,291 |
| Morgan Stanley | 963,256 | -4,269 |
| Nuveen, LLC | 873,560 | +151,212 |
| Arrowstreet Capital, Limited Partnership | 810,530 | +560,069 |
Insiders
16 insiders reported holding 659,780 shares in total, about $20.7M at the last price.
| Holder | Shares |
|---|---|
| Goff BrianChief Executive Officer, Director | 184,508 |
| Fouse Jacqualyn ADirector | 154,156 |
| Jones CeciliaChief Financial Officer | 54,998 |
| Gheuens SarahChief Medical Officer | 54,645 |
| Burns James WilliamChief Legal Officer | 49,306 |
| Milanova TsvetaChief Commercial Officer | 46,829 |
| Scadden DavidDirector | 20,419 |
| Ho MaykinDirector | 19,848 |
| Ballal Rahul D.Director | 15,230 |
| Smith CynthiaDirector | 15,230 |
Questions about AGIO
What does Agios Pharmaceuticals, Inc. do?
Agios Pharmaceuticals, Inc. is a company in the Health care sector, listed on NASDAQ as AGIO. Its shares trade on NASDAQ under the ticker AGIO.
What is Agios Pharmaceuticals, Inc.'s net worth?
Agios Pharmaceuticals, Inc. has a market value (market cap) of $1.9B at the latest share price, and shareholders' equity of $979.3M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Agios Pharmaceuticals, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $372.9M on revenue of $140.8M.
How much revenue does Agios Pharmaceuticals, Inc. make?
Over the twelve months to September 30, 2026 Agios Pharmaceuticals, Inc. reported revenue of $140.8M. That is 214.4% more than a year earlier.
When did Agios Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Agios Pharmaceuticals, Inc.'s next earnings report?
Agios Pharmaceuticals, Inc.'s next report is expected around February 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare AGIO with
Follow AGIO
Get an email when Agios Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Agios Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.